Form 4: Silo Pharma CFO Granted 50,000 Stock Options Under Equity Incentive Plan

Silo Pharma, Inc.'s Chief Financial Officer, Daniel E. Ryweck, was granted 50,000 stock options with an exercise price of $0.429, vesting on the one-year anniversary of the grant date.

Summary

• Daniel E. Ryweck, Chief Financial Officer of Silo Pharma, Inc. (SILO), was granted 50,000 stock options.
• The options have an exercise price of $0.429 per share.
• The grant date for these options was May 23, 2025.
• These options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan.
• One hundred percent (100%) of the shares subject to the option will vest on the one-year anniversary of the grant date, specifically May 23, 2026.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Daniel E. Ryweck beneficially owns 55,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for management alignment and retention, though it does not directly reflect operational or financial performance. It's a standard compensation practice.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The options were issued under an existing 2020 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The granted options are set to vest on May 23, 2026, indicating a future increase in the CFO's exercisable equity holdings, aligning his long-term incentives with the company's performance.

Management Comments

• The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan.
• One hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.

Industry Context

The granting of stock options to key executives is a standard practice across various industries, including biotechnology and pharmaceuticals, serving as a common mechanism for long-term incentive compensation and talent retention.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a widely accepted practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or BioNTech, though the specific size and exercise price of the grant would require a detailed comparison against peer group compensation benchmarks to assess its relative competitiveness.
• The vesting schedule of one year is a common approach to ensure executive retention and align interests over a medium-term horizon, consistent with typical equity incentive plans seen in publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of 50,000 stock options to Daniel E. Ryweck, the Chief Financial Officer, constitutes a related party transaction as it involves compensation provided by the company to an executive officer.

Stakeholder Impact

• Shareholders: The option grant aims to align the CFO's long-term interests with shareholder value creation, potentially leading to improved performance and governance.
• Employees: This transaction is part of the company's executive compensation strategy, which can influence overall compensation philosophy and morale.

Next Steps

• The granted options will vest on May 23, 2026, at which point they will become exercisable.

Key Dates

Keywords

Silo Pharma, stock options, executive compensation, Form 4, insider transaction, equity incentive plan, Daniel E. Ryweck, CFO